In 2025, the Fifth Circuit’s Zyla Life Sciences, LLC v. Wells Pharma of Houston, LLC included a passing, non-binding comment suggesting that brand-name manufacturers might sue compounders under state unfair-competition laws for selling unapproved “new drugs.” On August 4, 2026, a ruling from the U.S. District Court for the Southern District of Texas gave the clearest answer yet.
In Eli Lilly and Company v. Revive Rx, LLC (Civil Action No. H-23-3521), Judge Lee H. Rosenthal denied Revive Rx’s motion for judgment on the pleadings, letting Eli Lilly’s unfair-competition claims proceed under seven states’ laws. Eli Lilly alleges Revive Rx sells large volumes of compounded tirzepatide/vitamin B6 products that compete with its FDA-approved Mounjaro® and Zepbound® without the approvals a “new drug” would require. Here’s what the 43-page opinion means for compounding pharmacies and for the practices that buy from them.
What Happened in Court
Revive Rx asked the court to rule in its favor at the earliest possible stage, before discovery or trial, through a motion for judgment on the pleadings. These motions ask a court to decide a case based only on what has already been filed, and they rarely succeed. Revive Rx made three arguments:
- Compounded medications are not “new drugs” under the state laws at issue, so Revive Rx cannot be unfairly competing.
- Even if compounded drugs can be “new drugs,” violating a state’s new-drug law is not, by itself, an unfair trade practice.
- Connecticut and Washington give their state governments exclusive authority to enforce their food-and-drug statutes, which bars Eli Lilly from suing under those states’ unfair-competition laws instead.
The court rejected all three arguments and denied Revive Rx’s motion. That the motion failed doesn’t say much on its own. What matters more is the court’s reasoning along the way, which maps out the issues likely to decide this case, and others like it, going forward.
Key Takeaways for Compounding Pharmacies
Judge Rosenthal’s opinion addressed compounding pharmacies generally, without turning on whether a pharmacy operates as a 503A pharmacy (compounding for individual patients under a prescription) or a 503B outsourcing facility (compounding at larger scale under separate FDA registration).
1. Compounded Drugs Can Still Be “New Drugs” Under the Law
Revive Rx’s central argument was that compounding falls outside the statutory definition of a “new drug” altogether. The court disagreed. Under both federal law (21 U.S.C. § 321(p)) and the state statutes at issue, whether a drug is “new” turns on its composition, safety, and effectiveness — not on who made it or whether it was compounded under a prescription. Combining two otherwise-approved ingredients, such as tirzepatide and vitamin B6, can create an unapproved “new drug” if that specific combination is not generally recognized as safe and effective. Compounding a drug does not, by itself, exempt it from that analysis.
2. Compliance With Pharmacy Law Is Still Your Strongest Shield
None of this makes traditional compounding suspect. The court was careful to note that pharmacies compounding tailored medications for patients with genuine clinical needs — for example, a patient who is allergic to an inactive ingredient, cannot swallow the commercially available form, or needs a drug affected by a supply shortage — operate within safe harbors recognized under state and federal pharmacy law.
The opinion repeatedly distinguishes this kind of legitimate, patient-specific compounding from “large-scale compounding activity, third-party resale, or wholesale distribution” that looks more like unauthorized manufacturing.
What Practices Buying Compounded Drugs Should Know
Medical spas, wellness clinics, and prescribers who purchase compounded medications — particularly GLP-1s and other high-demand compounds — have a direct stake in how this litigation unfolds, even though they are not named as defendants.
1. Your Supply Chain Is Only as Secure as Your Pharmacy’s Compliance
If a compounding pharmacy you rely on becomes the target of a manufacturer lawsuit, a state board investigation, or an injunction, your supply of that medication can disappear with little notice. Reasonable due diligence on any pharmacy vendor includes:
- Confirming whether the pharmacy operates as a 503A pharmacy (compounding per individual prescription) or a 503B outsourcing facility (FDA-registered, larger-scale production), since different rules apply to each.
- Verifying the pharmacy holds valid, current licenses in both its home state and yours.
- Asking for documentation that bulk substances used in compounding come from FDA-permitted or USP-compliant suppliers.
2. Respect the “Commercial Availability” Principle
Compounding exists to meet needs that commercially available, FDA-approved drugs cannot — not to provide a cheaper version of a drug that is already readily on the market. If an FDA-approved option is available and appropriate for a patient, prescribing or dispensing a compounded alternative without a documented clinical reason increases legal exposure for both the pharmacy and the practice.
3. Don’t Market Compounded Products as Equivalent to the Brand-Name Drug
Part of Eli Lilly’s case rests on the allegation that Revive Rx is “trading on” Lilly’s reputation — built through years of clinical testing on its FDA-approved products — by implying that its compounded version is just as safe and effective. Practices should apply the same caution to their own marketing: describe compounded treatments by their chemical name (for example, “tirzepatide therapy”), avoid referencing brand names like Ozempic®, Wegovy®, or Mounjaro®, and disclose clearly that the product is compounded and not FDA-approved.
Action Steps for Pharmacies and Buying Practices
Whatever side of this transaction you are on, a few practical steps reduce your exposure:
- Audit compounding operations and vendor credentials against 503A/503B requirements, and confirm all licenses are current.
- Review marketing materials, websites, and social media for language that overstates approval status or implies equivalence to a brand-name drug.
- Update patient consent forms to clearly disclose that a medication is compounded, not individually FDA-approved, and may differ from the commercial product.
- Document the specific clinical reason — allergy, dosing need, shortage, or similar — for any compounded prescription not tied to an obvious commercial shortage.
Conclusion
The Eli Lilly v. Revive Rx ruling confirms that federal courts will hear unfair-competition claims against compounding pharmacies that stray into unauthorized, large-scale manufacturing. It also confirms that pharmacies and practices that compound and prescribe within the bounds of state and federal law have real, recognized defenses. The safest position is still the simplest one: know your regulatory limits, document your reasoning, and stay well inside them.
If you have questions about how this ruling affects your pharmacy’s compounding practices or your clinic’s vendor relationships, our healthcare regulatory team at Lengea Law is available to help.